Diabetic Retinopathy Laser Treatment

Diabetic retinopathy is the leading cause of blindness in working-age adults worldwide. Laser photocoagulation has been the cornerstone of advanced diabetic retinopathy treatment since the landmark Diabetic Retinopathy Study (DRS, 1976) and Early Treatment Diabetic Retinopathy Study (ETDRS, 1985). Two main laser techniques are used: (1) Macular laser (focal/grid) for clinically significant macular edema (CSME) — defined by ETDRS as retinal thickening within 500 micrometers of the foveal center, hard exudates within 500 micrometers of foveal center associated with adjacent retinal thickening, or retinal thickening at least 1 disc area in size with any portion within 1 disc diameter of foveal center. (2) Panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR) — defined by retinal neovascularization (neovascularization at the disc, NVD, or elsewhere, NVE), preretinal or vitreous hemorrhage, and severe non-proliferative diabetic retinopathy (NPDR) with high-risk features approaching PDR.

Macular laser (focal/grid) technique: focal laser targets identifiable leaking microaneurysms with 50-100 micrometer spot size, 0.05-0.1 second duration, and moderate intensity to produce a light gray-white burn. Grid laser applies a regular pattern of 100 micrometer spots in areas of diffuse leakage or capillary non-perfusion, sparing the foveal avascular zone (within 500 micrometers of foveal center) and the immediate parafoveal area. ETDRS demonstrated 50% reduction in moderate visual loss with timely macular laser. Modern role of macular laser has dramatically diminished after the DRCR.net Protocol I (2010) and Protocol T (2015) trials demonstrated superior visual outcomes with intravitreal anti-VEGF agents (ranibizumab, aflibercept, bevacizumab) for center-involving diabetic macular edema. Macular laser remains useful for non-center-involving CSME, persistent edema despite anti-VEGF therapy (rescue laser), focal areas of leakage outside the foveal area, and patients who cannot tolerate or afford anti-VEGF injections.

Panretinal photocoagulation (PRP) technique: 1500-2500 burns of 500 micrometer spot size, 0.05-0.2 second duration, applied with moderate intensity to produce gray-white burns sparing the macula (extending from outside the temporal vascular arcades and superotemporal/inferotemporal poles to ora serrata). Burns are applied 1-2 burn widths apart in 1-3 sessions to minimize macular edema exacerbation. The DRS demonstrated 50-60% reduction in severe visual loss (best-corrected visual acuity less than 5/200) over 5 years with PRP for PDR. Mechanism: PRP destroys ischemic peripheral retina, reducing total retinal oxygen demand and VEGF production, which leads to regression of neovascularization (NVD and NVE) and reduces risk of vitreous hemorrhage and tractional retinal detachment. Side effects of PRP: peripheral visual field constriction (10-20%), reduced night vision (40%), worsening of macular edema (especially if performed in single session — DRCR Protocol AA, single session vs split), color vision changes, choroidal detachment, exudative retinal detachment (rare), and rare neovascular glaucoma if PRP is delayed in advanced PDR. Modern PRP advances: pattern scanning lasers (PASCAL, NaviPlus, PASCAL Streamline) deliver multiple burns in a controlled pattern (typically 2x2, 3x3, 4x4, 5x5 grid) with shorter pulse durations (10-30 ms) and higher power, reducing patient discomfort, treatment time (multiple shots in single foot pedal press), and surrounding retinal damage. Anti-VEGF therapy (ranibizumab, aflibercept) is now an alternative or adjunct to PRP per DRCR Protocol S, demonstrating non-inferior visual outcomes with PDR but requiring continued injections (lifetime cost), more rapid response, less peripheral visual field loss, and useful for combined PDR and DME. PRP combined with anti-VEGF (combination therapy) is often used in clinical practice for severe PDR with vitreous hemorrhage. Indications for laser in modern practice: PDR (PRP), severe NPDR with high-risk features (consider PRP), CSME without center involvement (focal/grid laser), persistent DME despite anti-VEGF (rescue laser), iris or angle neovascularization (urgent PRP). Pre-laser workup: comprehensive eye exam, fundus photography, optical coherence tomography (OCT) for macular edema assessment, fluorescein angiography to identify leakage and capillary non-perfusion. Post-laser: monitor for treatment efficacy, macular edema worsening, neovascularization regression, and complications. Patient counseling on need for compliance, follow-up, and that laser is preventive of vision loss rather than restorative.